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Abstract
Activation of the focal adhesion kinase pp125FAK correlates with its phosphorylation on tyrosine residues and is
mediated by multiple receptor-ligand pairs. In platelets, pp125FAK phosphorylation is triggered by KIIbL3 integrin or FcQRII
receptor interaction with immobilized fibrinogen and IgG, respectively. In this study we used platelets as a model system to
explore the role of PI 3-kinase relative to pp125FAK phosphorylation. Treatment of the platelets with two PI 3-kinase
inhibitors, wortmannin and LY294002, inhibited in a dose-dependent manner KIIbL3-mediated platelet spreading on
fibrinogen having no effect on platelet spreading on IgG. Both inhibitors also completely abolished KIIbL3-mediated
pp125FAK phosphorylation but not pp72syk phosphorylation. Furthermore, FcQRII- and thrombin-induced pp125FAK
phosphorylation were not affected by wortmannin and LY294002. Finally, the PI 3-kinase inhibitors’ effect on KIIbL3-
mediated spreading and pp125FAK phosphorylation was reversed by phorbol ester treatment. These results establish that
the role of PI 3-kinase relative to pp125FAK phosphorylation in platelets is receptor type-specific yet essential for KIIbL3-
mediated cell spreading and pp125FAK phosphorylation. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Adhesive interactions and growth factors trigger
activation of the focal adhesion kinase pp125FAK
in multiple cell systems. Pp125FAK is an essential
signaling protein as evident from the fact that
pp125FAK knockout mice die before birth [1]. How-
ever, neither the exact role of this kinase nor the
pathways that are activated upstream and down-
stream from pp125FAK are currently fully under-
stood [2^6].
Platelet adhesion to ¢brinogen, mediated by the
integrin receptor KIIbL3, triggers spreading and the
induction of pp125FAK tyrosine phosphorylation
[7]. Both events are dependent on protein kinase C
(PKC) activation as well as ADP released by the
platelet itself [7,8]. Two additional platelet receptors,
integrin K2L1 and FcQRII, similarly trigger
pp125FAK phosphorylation upon platelet adhesion
to collagen and immunoglobulin, respectively. Integ-
rin K2L1 and FcQRII receptor-mediated pp125FAK
phosphorylation are KIIbL3-and ADP-independent,
yet PKC-dependent [7,9]. These observations suggest
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that alternative pathways may link the signaling ad-
hesion receptor to pp125FAK phosphorylation.
A correlation between integrin KIIbL3 and PI 3-ki-
nase activation was also noted in platelets. Immo-
bilized ¢brinogen [7,10] and an antibody that binds
to the L subunit of KIIbL3 (anti-LIBS6) [11] trigger
‘outside-in’ activation of KIIbL3. Both stimuli lead to
the generation of PtdIns(3,4)P2, one of the phospho-
inositides (PtdIns) produced by PI 3-kinase [12,13].
PtdIns(3,4)P2 was not detected in thrombin-stimu-
lated Glanzmann’s thrombasthenic platelets which
are KIIbL3-de¢cient [14]. Similarly, the RGDS tetra-
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Fig. 1. E¡ect of PI 3-kinase inhibitors on ¢brinogen- and IgG-induced protein tyrosine phosphorylation. (A) Platelets were kept in
suspension (SUS-UN; lane 1) or were added to ¢brinogen- (FBGN; lanes 2^9) coated plates. Prior to exposure to ¢brinogen, the pla-
telets were untreated (UN; lane 2) or treated for 10 min with 1, 3, 5 or 10 nM wortmannin (WORT; lanes 3, 4, 5, and 6, respec-
tively) or with 5, 10 or 25 WM LY294002 (LY; lanes 7, 8, and 9, respectively). The platelets were lysed in sample bu¡er and equal
amounts of protein were immunoblotted and probed mAb 4G10. (B^D) Platelets were kept in suspension (SUS-UN; lane 1) or were
added to ¢brinogen- (FBGN; lanes 2^4) or immunoglobulin- (IgG; lanes 5^7) coated plates. Prior to exposure to the protein-coated
surfaces, the platelets were untreated (UN; lanes 2 and 5) or treated for 10 min with wortmannin (WORT; 10 nM) (lanes 3 and 6) or
LY294002 (LY; 25 WM) (lanes 4 and 7). (B and C) Platelets were lysed in RIPA bu¡er. Lysates containing 200^300 Wg protein were
immunoprecipitated with a polyclonal antiserum to pp125FAK. The immunoprecipitates were Western blotted and probed with mAb
4G10 (B) or pp125FAK (C). (D) Platelets were lysed in sample bu¡er and equal amounts of protein were immunoblotted and probed
with mAb 4G10. (E and F) Platelets were untreated and adhered to ¢brinogen (FBGN; lanes 1, 3 and 4) or IgG (lane 2), or were
treated for 10 min with 30 nM wortmannin (WORT; lane 3) or 25 WM LY294002 (LY; lane 4) prior to adherence to ¢brinogen. Pla-
telets were lysed in RIPA, and lysates containing an equal protein concentration were immunoprecipitated with a polyclonal antiserum
to pp72syk. The immunoprecipitates were Western blotted and probed with mAb 4G10 (E) or pp72syk (F).
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peptide which blocks KIIbL3 engagement prevented
the accumulation of PtdIns(3,4)P2 in thrombin-
stimulated platelets [14,15]. RGDS also reduced the
movement of PI 3-kinase, KIIbL3, and several other
proteins to the detergent-insoluble fraction that
forms in thrombin-stimulated platelets [16]. Collec-
tively these data suggested that in the ‘outside-in’
pathway KIIbL3 may at least partially regulate PI
3-kinase activation leading to PI(3,4)P2 production.
Pp125FAK provides a docking site for multiple
signaling components [2,3,17]. Guan et al. were the
¢rst to show that in NIH 3T3 cells the p85 subunit of
PI 3-kinase was associated with pp125FAK [18]. A
p85/pp125FAK complex was also immunoprecipi-
tated from thrombin-activated platelet lysates [19].
Autophosphorylation of pp125FAK enhanced its in-
teraction with PI 3-kinase [18] and binding of the
proline-rich sequence of pp125FAK to the p85 sub-
unit enhanced the catalytic activity of PI 3-kinase
[19]. These data suggested that pp125FAK may act
upstream of PI 3-kinase. Rankin et al. [20] have sub-
sequently shown that inhibitors of PI 3-kinase pre-
vented PDGF-stimulated, but not bombesin-, endo-
thelin-, or phorbol ester-stimulated, pp125FAK
phosphorylation in Swiss 3T3 cells, suggesting that
PI 3-kinase may at times act upstream from
pp125FAK. Finally, in COS 7 cells PI 3-kinase in-
hibition had only a modest e¡ect on pp125FAK
phosphorylation triggered by integrin-mediated cell
binding to ¢bronectin [21]. Thus, the relationship
between PI 3-kinase and pp125FAK is most likely
cell-type and stimulus-speci¢c. The goal of this study
was to examine whether pp125FAK phosphoryla-
tion in platelets is dependent on PI 3-kinase activa-
tion.
Fig. 2. E¡ect of wortmannin and phorbol ester co-treatment on
protein tyrosine phosphorylation. (A and B) Platelets were
treated without (lanes 1 and 4) or for 10 min with wortmannin
(10 nM) (lanes 2 and 3). Subsequently, the platelets were
treated for 10 min with DMSO (lane 1) or phorbol ester
(PMA; 10 nM) (lanes 3 and 4), and were then added to the ¢-
brinogen-coated plates for 1 h. RIPA lysates were immunopre-
cipitated with the polyclonal antiserum to pp125FAK. The im-
munoprecipitates were Western blotted and probed with mAb
4G10 (A) or pp125FAK (B). (C) Puri¢ed platelets were treated
without (lanes 1 and 6) or for 10 min with 10 or 30 nM wort-
mannin (lanes 2^3 and 4^5, respectively). Subsequently, the pla-
telets were treated for 10 min with DMSO (lane 1) or PMA
(lanes 3, 5 and 6), and were then added to the ¢brinogen-
coated plates for 1 h. Platelets were lysed in sample bu¡er and
equal amounts of total protein were immunoblotted and probed
with mAb 4G10.
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2. Materials and methods
2.1. Platelet preparation
Human platelets were puri¢ed from freshly drawn
blood by gel ¢ltration as previously described [7].
For adhesion studies, polystyrene plates were coated
with ¢brinogen (100 Wg/ml; from Sigma) or IgG
(50 Wg/ml; from Sigma) as previously described [7].
Platelet morphology was examined by light micro-
scopy.
To examine the inhibitors’ e¡ect, platelets were
pre-incubated for 10 min with either wortmannin
or LY294002 (2-(4-morpholinyl)-8-phenyl-4H-1-ben-
zopyran-4-one) in 0.5% Me2SO4 (DMSO). Both in-
hibitors were purchased from Biomol. As a control,
platelets were treated with 0.5% DMSO alone for 10
min. Where indicated, the platelets were treated for
5 min with phorbol ester (10 nM; from Sigma) or for
10 min with mAb 7E3 (10 Wg/ml) kindly provided by
Dr. Barry Coller (Mount Sinai School of Medicine,
New York).
2.2. Immunoprecipitation and immunoblotting
Suspended and adherent platelets were lysed for
20 min in RIPA bu¡er (1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, 158 mM NaCl, 10 mM
Tris-HCl, pH 7.2, 1 mM sodium EGTA, 1 mM phen-
ylmethylsulfonyl £uoride, and 1 mM sodium vana-
date) to immunoprecipitate pp125FAK and p72syk.
The pp125FAK and p72syk antiserum were pur-
chased from Santa Cruz (FAK C-20, cat. # sc-558
and Syk(LR) cat. # sc-573). The lysates were clari¢ed
by centrifugation at 15 000Ug for 10 min at 4‡C, and
were subsequently analyzed for protein content using
the Pierce BCA reagents. Equal amounts of protein
were then subjected to immunoprecipitation. The ly-
sates were ¢rst pre-cleared for 1 h with protein A/G
plus-agarose (from Santa Cruz) and then incubated
with the antiserum to pp125FAK or p72syk for at
least 2 h. The immune complexes were precipitated
with protein A/G plus-agarose. The immunoprecipi-
tates prepared for Western blot analysis were washed
four times with RIPA bu¡er and eluted in Laemmli
sample bu¡er.
Total cell lysates were prepared by lysis of the
platelets in sample bu¡er (66 mM Tris-HCl, pH
7.4, 2% SDS) at 90‡C. The samples were subse-
quently processed as previously described [9]. Lysates
containing equal amounts of protein were subjected
to immunoblotting analysis with mAb 4G10 (from
Upstate Biotechnology) or the antiserum to
pp125FAK. Immunoreactivity was detected using
the ECL kit from Amersham and autoradiography.
3. Results
3.1. PI 3-kinase inhibitors abrogate ¢brinogen- but
not IgG-stimulated platelet spreading and
pp125FAK phosphorylation
Pp125FAK phosphorylation in platelets is closely
linked to spreading as demonstrated by the ability of
Fig. 3. E¡ect of PI 3-kinase inhibitors on thrombin-induced
pp125FAK phosphorylation. Platelets were kept in suspension
untreated (UN; lanes 2) or stirred in suspension with 1 U/ml
thrombin for 10 min (lanes 3^6). The thrombin-stimulated pla-
telets were either untreated (UN; lanes 3) or pretreated for
10 min with LY294002 (LY; 25 WM), wortmannin (WORT;
10 nM), or with mAb 7E3 (10 Wg/ml) to inhibit ¢brinogen-
KIIbL3 receptor interaction. Platelets were lysed in RIPA bu¡er
and immunoprecipitated with a control antiserum (lanes 1) or
the pp125FAK antiserum (lanes 2^6). Pp125FAK phosphoryl-
ation was examined as described in the legend to Fig. 1. The
blots shown in A and B were probed with mAb 4G10 and the
pp125FAK antiserum, respectively.
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several inhibitors to simultaneously prevent both
events. To examine the relationship among
pp125FAK phosphorylation, PI 3-kinase activation,
and platelet spreading, we have treated puri¢ed pla-
telets with the two unrelated and well characterized
PI 3-kinase inhibitors, wortmannin and LY294002.
Control platelets treated with 0.5% DMSO alone
and inhibitor-treated platelets were added to ¢brino-
gen- or IgG-coated plates for 1 h. Treatment of the
platelets with wortmannin at a concentration equal
to or greater than 10 nM, or with LY294002 at a
concentration of 10 WM or higher, prevented platelet
spreading on ¢brinogen; a partial inhibitory e¡ect
was observed with wortmannin at 5 nM and
LY294002 at 2.5 WM (data not shown). In contrast,
the inhibitors had no e¡ect on platelet spreading on
IgG. We have previously shown that platelet spread-
ing on ¢brinogen correlates with the phosphorylation
of two proteins that migrate with an electrophoretic
mobility of 101 and 105 kDa (pp101/105), respec-
tively [7,8]. As shown in Fig. 1A, wortmannin and
LY294002 abrogated the phosphorylation of pp101/
105 in a dose-dependent manner and within the same
concentration range needed to inhibit spreading on
¢brinogen and as demonstrated by Kovacsovics et al.
[12], PI 3-kinase activation in platelets.
To examine the inhibitors’ e¡ect on the induc-
tion of pp125FAK phosphorylation, platelet lysates
were immunoprecipitated with an antiserum to
pp125FAK. The immunoprecipitates were analyzed
by immunoblotting with the mAb against phospho-
tyrosine, 4G10 (Fig. 1B), and the pp125FAK antise-
rum (Fig. 1C). As shown in Fig. 1B, both wortman-
nin (Fig. 1B, lane 3) and LY294002 (Fig. 1B, lane 4)
completely inhibited the ¢brinogen-induced
pp125FAK phosphorylation. In contrast, densito-
metric analysis of the data shown in Fig. 1B,C as
well as data obtained in two additional experiments
revealed a less than 20% reduction in the induction
of pp125FAK phosphorylation following treatment
of the platelets with wortmannin or LY294002 as
compared to untreated platelets. Consistent with
this di¡erential e¡ect, wortmannin and LY294002
abrogated the phosphorylation of pp101/105 trig-
gered by ¢brinogen but not by IgG (Fig. 1D).
Platelet adhesion to ¢brinogen also triggers weak
phosphorylation of yet another protein tyrosine ki-
nase, p72syk [9,22]. In contrast, platelet adhesion to
immobilized IgG or FcQRII receptor cross linking
trigger robust activation of p72syk ([22,23] and Fig.
1E,F). Wortmannin and LY294002 did not prevent
KIIbL3-mediated pp72syk phosphorylation (Fig.
1E,F). Densitometric analysis of the data shown in
Fig. 1E,F revealed no e¡ect of wortmannin and a
less than 15% reduction in the induction of pp72syk
phosphorylation following treatment of the platelets
with LY204002 as compared to untreated platelets.
Consistent with data reported by others [9,24], these
data demonstrated that KIIbL3-mediated pp125FAK
and p72syk phosphorylation are independently regu-
lated. FcQRII-induced p72syk phosphorylation was
also not a¡ected by the PI 3-kinase inhibitors (data
not shown). Taken together these data indicate that
PI 3-kinase is speci¢cally involved in the regulation
of KIIbL3-mediated pp125FAK phosphorylation and
platelet spreading on ¢brinogen.
3.2. Phorbol ester reverses the inhibitory e¡ect of
wortmannin on ¢brinogen-induced pp125FAK
phosphorylation and platelet spreading
PKC is an integral component of the KIIbL3-medi-
ated signaling cascade leading to pp125FAK phos-
phorylation [8]. These data, in conjunction with data
presented in Fig. 1, raised the questions of whether
there is a link between the activation of PKC and PI
3-kinase, and if so, in what sequential order these
two signaling components may be linked. To search
for a potential association between PKC and PI
3-kinase, wortmannin-treated platelets were subse-
quently treated with the PKC activator, phorbol es-
ter. Addition of phorbol ester to platelets pretreated
with either 10 nM or 30 nM wortmannin restored
spreading (data not shown) and the induction of
pp125FAK and pp101/105 phosphorylation (Fig.
2). In fact, treatment of the platelets with phorbol
ester alone or with wortmannin followed by phorbol
ester enhanced pp125FAK phosphorylation by about
2-fold relative to the phosphorylation observed in
DMSO-treated platelets. These data suggested that
PI 3-kinase may act upstream of PKC in the path-
way leading from KIIbL3 to pp125FAK phosphoryla-
tion. These data, however, do not exclude the possi-
bility that the phorbol ester-induced PKC activation
triggers a parallel signaling pathway independent of
PI 3-kinase activation.
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3.3. E¡ect of PI 3-kinase inhibitors on
thrombin-induced pp125FAK phosphorylation
We next asked whether PI 3-kinase a¡ects throm-
bin-induced pp125FAK activation. As a control for
these studies platelets were treated with mAb 7E3, an
inhibitor of ¢brinogen-KIIbL3 interaction and platelet
aggregation [25]. Treatment of the platelets with
mAb 7E3 prior to the addition of thrombin blocked
aggregation and pp125FAK phosphorylation (Fig. 3
and previously demonstrated [26]). In contrast, wort-
mannin or LY294002 reduced the thrombin-induced
pp125FAK phosphorylation by 17% and 56% respec-
tively. Thus, PI 3-kinase appears to play a secondary
role relative to the activation of pp125FAK when
thrombin is the stimulating agonist.
4. Discussion
The goal of this study was to establish whether PI
3-kinase regulates signaling events that e¡ect spread-
ing and pp125FAK phosphorylation in platelets.
Since platelets are not amenable to genetic manipu-
lations ex vivo, the role of PI 3-kinase was investi-
gated using two well characterized PI 3-kinase inhib-
itors, wortmannin and LY294002. Wortmannin is a
cell-permeate fungal metabolite that inhibits PI
3-kinase by irreversibly binding to the p110 catalytic
subunit of PI 3-kinase (IC50 3 nM) [27] whereas
LY294002 is a competitive antagonist for the ATP
binding site of PI 3-kinase (IC50 1.4 WM) [28]. We
report that wortmannin and LY294002 completely
inhibit KIIbL3-mediated platelet spreading on ¢brino-
gen and pp125FAK phosphorylation. The e¡ect was
dose-dependent; complete inhibition of pp125FAK
phosphorylation was obtained with wortmannin at
a concentration of 10 nM or higher and LY294002
at a concentration equal to or greater than 25 WM.
Kovacsovics et al. have shown that LY294002 at a
concentration of 25 WM and wortmannin at a con-
centration of 100 nM inhibit PI 3-kinase activation
in platelets stimulated with the thrombin receptor
activating peptide TRAP [12]. Integrin-stimulated
PI 3-kinase activation in COS 7 cells was similarly
prevented by 100 nM wortmannin and 25 WM
LY294002 [21]. It is important to note, however,
that even within this concentration range the inhib-
itory e¡ect of wortmannin may not be limited to PI
3-kinase alone [29]. In contrast, wortmannin and
LY294002 did not a¡ect KIIbL3-mediated pp72syk
phosphorylation. Furthermore, FcQRII receptor-in-
duced pp125FAK phosphorylation was not a¡ected
by the PI 3-kinase inhibitors. Based on these data we
conclude that PI 3-kinase speci¢cally regulates
KIIbL3-mediated platelet spreading and pp125FAK
phosphorylation.
Two PI 3-kinase isotypes have been identi¢ed in
platelets, a heterodimeric complex composed of a
85-kDa regulatory subunit and a 110-kDa catalytic
subunit (p85/p110) and PI 3-kinase Q, which is com-
posed of a single p110Q unit [30]. All current data
indicate that the p85 subunit of PI 3-kinase binds
to pp125FAK; a p85/pp125FAK complex was im-
munoprecipitated both from ¢bronectin-adherent
NIH 3T3 cells and from thrombin-activated platelets
[18,19]. These data suggest that p85/p110 rather than
PI 3-kinase Q may associate with the KIIbL3-
pp125FAK pathway. However, since both PI 3-ki-
nases are a¡ected by wortmannin [31] additional
studies are necessary to con¢rm this hypothesis.
The KIIbL3 to PI 3-kinase-dependent step may lie
upstream of PKC since phorbol ester treatment re-
versed the PI 3-kinase inhibitors’ e¡ect. Phorbol ester
treatment similarly reversed the inhibitory e¡ect of
apyrase [8] on pp125FAK phosphorylation suggest-
ing that PKC activation is key to KIIbL3-mediated
pp125FAK phosphorylation in platelets. Pp125FAK
phosphorylation in ¢bronectin-adherent CHO cells is
also PKC-dependent [32]. In vitro, phosphoinositides
up-regulate the kinase activity of the novel PKC-N,
-O, and -R isoforms, and the atypical PKC-j isoform
[33,34]. Two of these isoforms, PKC-N and -j, are
expressed in platelets [35,36]. Data obtained in our
laboratory suggest that platelet adhesion to ¢brino-
gen does not trigger a signi¢cant increase in the ki-
nase activity of PKC-N [42]. Thus, an intermediate
other than PKC-N most likely regulates the pathway
from KIIbL3 to pp125FAK phosphorylation.
The ability of D3- and D4-phosphoinositides to
uncap actin ¢laments may provide an alternative
and/or additional mechanism by which these phos-
phoinositides could regulate cell spreading and
pp125FAK phosphorylation [37,38]. Actin ¢lament
assembly is dependent on the availability of fast-
growing ends, also known as barbed ends. In resting
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platelets the barbed ends are blocked or ‘capped’ by
proteins such as gelsolin, which are removed upon
platelet activation. Hartwig et al. [37] showed that
when added to n-octyl-L-glucopyranoside-permeabi-
lized platelets, PI(4,5)P2, PI(3,4)P2 and PI(3,4,5)P3
increased the number of actin barbed ends by sev-
eral-fold. Furthermore, PI(4,5)P2 and PI(3,4)P2 ef-
fectively inhibited the interaction between gelsolin
and actin which could explain the correlation be-
tween the increase in D3- and D4-phosphoinositides
and the number of barbed ends [37,38]. Both throm-
bin and phorbol ester induce the synthesis of D3 and
D4 phosphoinositides in platelets. In thrombin-
stimulated platelets actin ¢laments assembly was
not a¡ected by PI 3-kinase inhibitors, while the op-
posite was noted in phorbol ester-stimulated platelets
[38]. Consistent with this observation, we found that
PI 3-kinase inhibitors did not a¡ect thrombin-in-
duced pp125FAK phosphorylation. These data fur-
ther indicate that both PI 3-kinase-dependent and PI
3-kinase-independent pathways lead to pp125FAK
phosphorylation in platelets.
The e¡ect of the cytoskeleton organization on
pp125FAK phosphorylation has been evident since
the initial observation, by now reproduced in several
model systems [39,40], that inhibition of actin ¢la-
ment assembly by cytochalasin D prevents
pp125FAK phosphorylation in platelets [7,26].
Chrzanowska-Wodnicka and Burridge [41] have sub-
sequently shown that myosin light chain kinase in-
hibitors trigger loss of stress ¢bers, focal adhesions
and a decrease in pp125FAK phosphorylation.
Based on these and other data, theses authors pro-
posed that pp125FAK phosphorylation is dependent
on integrin receptor clustering which in turn is regu-
lated by the tension produced by actin ¢laments [4].
The model suggests that disruption of the actin cy-
toskeleton a¡ects integrin aggregation leading to an
inhibition of pp125FAK phosphorylation. The oppo-
site should hold true for activators of the cytoskele-
ton assembly. If D3 phosphoinositides produced as a
result of KIIbL3 ligation regulate the cytoskeleton or-
ganization, this model could provide an explanation
for the e¡ect of PI 3-kinase on KIIbL3-mediated
pp125FAK phosphorylation.
In summary, we have shown that PI 3-kinase reg-
ulates platelets spreading and pp125FAK phospho-
rylation mediated by KIIbL3 but not by the FcQRII
receptor or thrombin. Further studies are required to
establish the exact mechanism by which PI 3-kinase
a¡ects platelet spreading and pp125FAK phospho-
rylation in platelets.
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